These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1096571)

  • 1. Parkinsonism induced by dopaminergic antagonists.
    Hornykiewicz O
    Adv Neurol; 1975; 9():155-64. PubMed ID: 1096571
    [No Abstract]   [Full Text] [Related]  

  • 2. [The antipsychotic action of neuroleptics and basal ganglia function].
    Arushanian EB
    Farmakol Toksikol; 1973; 26(4):481-9. PubMed ID: 4151298
    [No Abstract]   [Full Text] [Related]  

  • 3. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
    [No Abstract]   [Full Text] [Related]  

  • 4. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M; Rojas P; Kravzov J; Rios C
    Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973
    [No Abstract]   [Full Text] [Related]  

  • 5. Actions of dopaminergic agonists on cyclic AMP production in rat brain homogenates.
    Iversen LL; Horn AS; Miller RJ
    Adv Neurol; 1975; 9():197-212. PubMed ID: 167565
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical evaluation of AHR-2244 a new psychotherapeutic agent.
    Johnson DN; Funderburk WH; Ward JW
    Arch Int Pharmacodyn Ther; 1974 Oct; 211(2):326-40. PubMed ID: 4477709
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathophysiology of schizophrenia and the striatum.
    Klawans HL; Goetz C; Westheimer R
    Dis Nerv Syst; 1972 Nov; 33(11):711-9. PubMed ID: 4266033
    [No Abstract]   [Full Text] [Related]  

  • 8. [The participation of the dopaminergic system of the striatum in the regulation of catalepsy in mice and rats of different genotypes].
    Skrinskaia IuA; Popova NK; Nikulina EM; Kulikov AV
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1997; 47(6):1032-9. PubMed ID: 9472169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexisting tardive dyskinesia and parkinsonism: a case report.
    De Fraites EG; Davis KL; Berger PA
    Biol Psychiatry; 1977 Apr; 12(2):267-72. PubMed ID: 857938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stress-induced neurological impairments in an animal model of parkinsonism.
    Snyder AM; Stricker EM; Zigmond MJ
    Ann Neurol; 1985 Nov; 18(5):544-51. PubMed ID: 3935041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
    Havemann U
    Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
    [No Abstract]   [Full Text] [Related]  

  • 12. A dopaminergic-cholinergic mechanism in production of psychotic symptoms.
    Friedhoff AJ; Alpert M
    Biol Psychiatry; 1973 Apr; 6(2):165-9. PubMed ID: 4709131
    [No Abstract]   [Full Text] [Related]  

  • 13. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
    Marsden CD
    Mod Trends Neurol; 1975; 6():141-66. PubMed ID: 127927
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of drugs on metoclopramide-induced catalepsy and increase in striatal homovanillic acid content.
    Ahtee L
    Br J Pharmacol; 1975 Mar; 53(3):460P. PubMed ID: 1169083
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cellular effect of neuroleptics].
    Kuschinsky K
    Dtsch Med Wochenschr; 1975 Jun; 100(25):1405-8. PubMed ID: 237751
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
    Kucherianu VG; Kryzhanovskiĭ GN; Kudrin VS; Iurasov VV; Nikushkin EV; Zhigal'tsev IV
    Biull Eksp Biol Med; 1999 May; 127(5):502-5. PubMed ID: 10399565
    [No Abstract]   [Full Text] [Related]  

  • 17. Specific involvement of striatal D1 and D2 dopamine receptors in the neuroleptic catalepsy in rats.
    Wardas J; Pietraszek M; Ossowska K; Wolfarth S
    Pol J Pharmacol; 1995; 47(4):349-53. PubMed ID: 8616516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
    Frohna PA; Rothblat DS; Joyce JN; Schneider JS
    Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 Oct; 154(2):353-63. PubMed ID: 15313023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of liposomal form of L-Dopa on the level of dopamine, its metabolites, and phospholipid metabolism in the striatum of mice with experimental parkinsonian syndrome].
    Iurasov VV; Podgornyĭ GI; Kucherianu VG; Kudrin VS; Nikushkin EV; Zhigal'tsev IV; Sandalov IuG; Kaplun AP; Shvets VI; Kryzhanovskiĭ GN
    Biull Eksp Biol Med; 1996 Dec; 122(12):614-7. PubMed ID: 9280455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.